The Association of Cancer Care Centers offers education and resources to help multidisciplinary cancer care teams stay informed of disease-specific advances, deploy strategies for effective integration into practice, and engage in bi-directional learning.
Patients with rare diseases and their families often feel isolated and overlooked, with many medical questions left unanswered and few people who can empathize with their condition. Rare Disease Day is observed globally each year to bring awareness for diseases and the people behind them by promoting the challenges these rare medical journeys pose for patients and caregivers.
To help teams navigate treatment decisions for Relapsed/refractory (R/R) follicular lymphoma (FL), ACCC developed an Effective Practice Guide (EPG) that focuses on practical strategies for delivering high-quality care.
September is Gynecologic Cancer Awareness Month, a chance to highlight cancers that originate in the endometrium, ovary, and cervix, and to recognize efforts to improve patient outcomes for cancer types with poor prognoses and limited treatment options.
September is Blood Cancer Awareness month, an opportunity to spotlight the broad category of diseases that include leukemia, lymphoma, plasma cell neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms.
CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center’s community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy.
Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy.
In this episode, CANCER BUZZ speaks with Keri Halsema, NP, MSN, RN, nurse practitioner in the Blood Disorders Center at the University of Colorado Anschutz about the factors that influence treatment choices and the use of menin inhibitors to treat relapsed or refractory AML.
Navigating the growing complexity of bladder cancer care is essential to improving patient access and treatment closer to home. In this episode, CANCER BUZZ speaks with Suzanne Merrill, MD, urologic oncologist at Colorado Urology about barriers and solutions to delivering high-quality bladder cancer care in community settings. CANCER BUZZ also speaks with Patrick Hensley, MD, urologist at University of Kentucky Markey Cancer Center, about implementing the Delivering High-Quality Bladder Cancer Care infographic in the community setting. Created by ACCC and BCAN, the infographic describes the 10 elements of excellent bladder cancer care. Cancer programs that align their practices with these guidelines can join a public registry so that patients and caregivers can identify quality bladder cancer care close to where they live.
Bladder cancer remains a prevalent disease with significant disparities in care, particularly in underserved populations. To address this, ACCC launched a national quality improvement initiative in three phases: 1. assessment and preparation, 2. action plan implementation, and 3. monitoring for continuous improvement. Dr. Samuel Washington, from the University of California, San Francisco, discussed the initiative’s early findings, highlighting site-specific approaches.
In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices.
In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-basedmanagement of treatment-related adverse events can serve this patient population.
In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.
Learn how multidisciplinary providers can enhance care for hepatocellular carcinoma patients by improving care capacity and coordination.
With disparate breast cancer outcomes, lack of messages of hope, and limited available support for Black women, Rev. Tammie and her late sister were inspired to co-found Carrie’s TOUCH in 2006.
For detailed information about planning a skin cancer screening, download the Academy’s Plan an Event Toolkit at www.SpotSkinCancer.org.
Presented at Journal of the Advanced Practitioner in Oncology (JADPRO) Live 2024 in Grapevine, Texas.
This is a visual representation of an online publication from the American Society of Clinical Oncology 2024 Annual Meeting, May 31 – June 4, 2024.
Presented at the San Antonio Breast Cancer Symposium®- December 5-9, 2023.
This is a visual representation of an online publication from the American Society of Clinical Oncology 2022 Annual Meeting, June 3 - 7, 2022.